<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480308</url>
  </required_header>
  <id_info>
    <org_study_id>paravertebral block</org_study_id>
    <nct_id>NCT03480308</nct_id>
  </id_info>
  <brief_title>Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery</brief_title>
  <official_title>Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with&#xD;
      bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with&#xD;
      bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast&#xD;
      surgery.&#xD;
&#xD;
      Patients will receive ultrasound guided paravertebral block and stratified into 3 groups&#xD;
      according to medication used :&#xD;
&#xD;
      Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml ,&#xD;
      dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will receive ultrasound guided paravertebral block and stratified into 3 groups according to medication used :&#xD;
Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization Will be Done Using Computer Generated Tables</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first analgesic request</measure>
    <time_frame>one day postoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pain assessment</measure>
    <time_frame>one day postoperatively</time_frame>
    <description>Pain assessment by the aid of Visual analogue scale (VAS) Ranging from 0=no pain, 10=excruciating pain higher values represent worse outcome</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Paravertebral Block</condition>
  <arm_group>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block</description>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block</description>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivacaine</description>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years.&#xD;
&#xD;
          -  Sex: females&#xD;
&#xD;
          -  ASA physical status: I-II.&#xD;
&#xD;
          -  Operation: major breast surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patient refusal.&#xD;
&#xD;
          -  History of cardiac disease, psychological disorders, respiratory diseases including&#xD;
             asthma, renal or hepatic failure.&#xD;
&#xD;
          -  Coagulation disorders.&#xD;
&#xD;
          -  Infection at the puncture site&#xD;
&#xD;
          -  Allergy to study medications.&#xD;
&#xD;
          -  Chronic use of pain medications.&#xD;
&#xD;
          -  Respiratory tract in¬fection within the last 2 weeks.&#xD;
&#xD;
          -  Neurological deficit&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amonios khalil</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of medicine-Assiut university-Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amonios khalil</last_name>
    <phone>01023466456</phone>
    <email>amonios_khalil@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amonios Khalil gerges</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amonios Khalil</last_name>
      <phone>01023466456</phone>
      <email>amonios_khalil@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amonios khalil</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

